ArticlePoultry science2026
Development of a recombinant chimeric Newcastle disease virus-vectored vaccine conferring single-dose, triple protection against genotype VII NDV, IBDV, and H9N2 AIV.
Article in Poultry science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Newcastle disease, infectious bursal disease, and H9N2 avian influenza critically threaten the poultry industry worldwide. To achieve single-dose protection against all three pathogens, a recombinant chimeric Newcastle disease virus (NDV) vector vaccine was developed using a genotype-matched strategy. The fusion and hemagglutinin-neuraminidase genes of the LaSota vaccine strain were replaced with those from a prevalent genotype VII virulent NDV strain. The hemagglutinin gene of H9N2 avian influenza virus (AIV) and the VP2 gene of a very virulent infectious bursal disease virus (IBDV) strain were inserted between the P/M and F/HN gene junctions, respectively. The resulting virus, rLaS-VIIF/HN-HA-VP2, exhibited low pathogenicity (intracerebral pathogenicity index = 0.20; mean death time > 168 h) and replication kinetics similar to the parental strain. A single ocular/nasal dose in specific-pathogen-free chickens elicited strong antibody responses: ELISA titers >3000 against IBDV, hemagglutination inhibition titers of 4.8 log₂ against H9N2 AIV, and significant titers against genotype VII NDV. Challenge experiments at 21 days post-immunization showed complete protection against lethal infection with very virulent IBDV, H9N2 AIV, and genotype VII NDV. Vaccinated chickens displayed no mortality or clinical signs, reduced viral shedding, and minimal tissue damage. These findings demonstrate that rLaS-VIIF/HN-HA-VP2 is a safe and effective single-dose trivalent vaccine candidate, suitable for integrated control of three major avian diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.